Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti‐immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis

@article{RacinePoon1997EfficacyPA,
  title={Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti‐immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis},
  author={Amy Racine‐Poon and Luigi Botta and Tse Wen Chang and Frances M. Davis and Daniel Gygax and Ruey S. Liou and Patricia Rohane and Theophil Staehelin and A. M. P. Van Steijn and W. Frank},
  journal={Clinical Pharmacology \& Therapeutics},
  year={1997},
  volume={62}
}
The pharmacological basis of anti-IgE therapy
  • T. Chang
  • Biology, Medicine
    Nature Biotechnology
  • 2000
TLDR
The structural basis of the specificity of the anti-IgE antibodies and pertinent results from in vitro experiments, animal model studies, and human clinical trials are analyzed in an attempt to provide a cogent pharmacological interpretation of the therapeutic effects of anti- IgE therapy in both the near- and long term.
Antibody pharmacokinetics and pharmacodynamics.
TLDR
The U.S. Food and Drug administration has approved several polyclonal antibody preparations and at least 18 monoclonal antibody preparations (antibodies, antibody fragments, antibody fusion proteins, etc.) which are associated with several interesting pharmacokinetic characteristics.
Past, present, and future of anti‐IgE biologics
TLDR
The molecular properties of past and present anti‐IgE biologicals are highlighted and concepts that might improve treatment efficacy of future drug candidates are suggested.
Anti-IgE Therapy
TLDR
Omalizumab, a recombinant humanized IgG1 antibody with a unique set of binding specificities toward human IgE, has been approved in the United States and Australia for treating adult and adolescent patients with moderate to severe asthma and for protecting against anaphylactic reactions to peanuts.
Molecular, Biologic, and Pharmacokinetic Properties of Monoclonal Antibodies: Impact of These Parameters on Early Clinical Development
TLDR
This review provides an overview of the molecular, biochemical, and pharmacokinetic properties and clinical development history of Mabs and details how these factors currently affect the scope and design of early clinical development strategies for these drug candidates.
Generation of therapeutic antibody responses against IgE through vaccination
TLDR
The results suggest that active immunization against IgE has the potential to become a therapeutic method for humans and appears to be safe to use as an antigen.
Allergen-Induced Inflammation and the Role of Immunoglobulin E (IgE)
TLDR
Existing strategies to treat allergic disorders beyond simple allergen avoidance focus on diminishing or eliminating the recurrent and/or persistent signs and symptoms that characterize the allergic response, but a new strategy has been developed that uses antibodies directed against immunoglobulin E to prevent it from binding to cells bearing its receptors and thus neutralizing the allergy response before it begins.
Allergen-induced inflammation and the role of immunoglobulin E (IgE).
TLDR
Existing strategies to treat allergic disorders beyond simple allergen avoidance focus on diminishing or eliminating the recurrent and/or persistent signs and symptoms that characterize the allergic response, but a new strategy has been developed that uses antibodies directed against immunoglobulin E to prevent it from binding to cells bearing its receptors and thus neutralizing the allergy response before it begins.
Pharmacokinetics and Pharmacodynamics of Biotech Drugs
TLDR
Pharmacokinetic/pharmacodynamic concepts are likely to continue and expand their role as a fundamental factor in the successful development of biotechnologically derived drug products in the future.
...
...

References

SHOWING 1-10 OF 18 REFERENCES
The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.
TLDR
The use of anti-human IgE antibody is safe and effective in reducing serum IgE levels in atopic individuals and provides a potential therapeutic approach to the treatment of atopic diseases.
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
TLDR
This chimeric form of 17-1A mAb has an approximate 6-fold longer circulation time and appears to be substantially less immunogenic than its murine counterpart, which may provide an advantage in the clinical application of such chimeric molecules in therapeutic trials in humans.
Monoclonal Antibodies Specific for Human IgE-Producing B Cells: A Potential Therapeutic for IgE-Mediated Allergic Diseases
TLDR
Evidence is reported for the existence of antigenic epitopes on IgE that are accessible on Ig E-secreting B cells but not on other cells bearing IgE.
A sensitive and specific two-site enzyme-immunoassay for human calcitonin using monoclonal antibodies.
A highly sensitive, specific and rapid two-site enzyme-immunometric assay (EIA) for the measurement of immunoreactive (ir) human calcitonin (hCT) in human plasma was developed using high-affinity
Attenuation of allergic airway inflammation in IL‐4 deficient mice
  • G. Brusselle, J. Kips, H. Bluethmann
  • Biology, Medicine
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 1994
TLDR
Results indicate that IL‐4 is a central mediator of allergic airway inflammation, regulating antigen‐induced eosinophil recruitment into the airways by a T cell dependent mechanism.
Interleukin-4 is required for the induction of lung Th2 mucosal immunity.
TLDR
IL-4 is central both to the induction of a local Th2 response and to the development of eosinophilic inflammation of the lung, with a sequential involvement of IL-4 and IL-5.
New concepts of IgE regulation.
TLDR
It is demonstrated that in certain established immune situations the IgE response may become independent of IL-4, namely in the spontaneous in vitro IgE expression of cells from atopic individuals as well as in an in vitro antigen-induced secondary IgEresponse of spleen cells derived from previously immunized mice.
Studies on the Retention of Passively Transferred Antibodies in Man
Abstract. Catabolism of intravenously or intramuscularly administered human immunoglobulin in man was studied by the administration of HBs antibodies at a high titer and analysis with a highly
Hybridoma production by simplified avidin-mediated electrofusion.
Immunology: The science of self-nonself discrimination
Well, someone can decide by themselves what they want to do and need to do but sometimes, that kind of person will need some immunology the science of self nonself discrimination references. People
...
...